BioXcel Turns To Commercialization With Positive Phase III Data In Agitation

The company is developing a sublingual thin film of dexmedetomidine that could be used to treat agitation in a wide range of indications after planned initial launches in schizophrenia and bipolar disorder.

soccer ball in goal
BioXcel scored in two Phase III trials • Source: Shutterstock

BioXcel Therapeutics, Inc.'s first potential drug candidate – a sublingual thin film of dexmedetomidine (BXCL501) – met the primary endpoints of two Phase III clinical trials, resulting in rapid and durable reductions in agitation in schizophrenia and bipolar disorder. The company announced the positive data from the SERENITY I and SERENITY II trials on 20 July and said it was turning its focus to regulatory filings and commercialization.

The company is targeting a regulatory filing in the first quarter of 2021 and investors applauded the news. BioXcel's stock price has been growing substantially throughout the year, up 317%...

More from Strategy

More from Business

Challenging Environment For Biopharma Is A Tailwind For Royalty Pharma

 

The royalty revenue stream acquirer has around 40 products in its portfolio and expects to generate roughly $3bn this year. Head of R&D and investments Marshall Urist talked about the investment strategy at the RBC Healthcare Conference.

Finance Watch: SV Closes Second Dementia Discovery Fund, Exceeding $250m Goal

 
• By 

Private Company Edition: SV Health Investors revealed the final closing of its second Dementia Discovery Fund. Also, Eikon cut nearly 15% of its staff, Pathos AI raised $365m in series D venture capital and CellCentric completed a $120m series C round, among other financings.

Sanofi Makes Alzheimer’s Bet With Vigil Buy

 
• By 

The French drugmaker is expanding its neurology activities with the $470m deal.